Stockscreener 앱 받기
20.67
2.38%
0.48
Alto Neuroscience Inc 주식(ANRO)의 최신 뉴스
Alto Plunges 8.96% Despite Bullish Technicals - Bitget
Alto Neuroscience (NYSE:ANRO) Trading Down 5.5%What's Next? - MarketBeat
Alto Neuroscience CFO Nick Smith on Firm’s $120 Million Private Placement - Yahoo Finance
NYSE Content Update: Alto Neuroscience Raises $120 Million to Fund Development of ALTO-207 - Investing News Network
Alto Neuroscience, Inc.(NYSE: ANRO) added to S&P Pharmaceuticals Select Industry Index - marketscreener.com
If You Invested $1,000 in Alto Neuroscienc (ANRO) - Stock Titan
Alto Neuroscience (NYSE:ANRO) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Alto Neuroscience Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Analysts Offer Insights on Healthcare Companies: Alto Neuroscience, Inc. (ANRO), Johnson & Johnson (JNJ) and InspireMD (NSPR) - The Globe and Mail
HC Wainwright Issues Negative Estimate for ANRO Earnings - MarketBeat
Analysts Offer Insights on Healthcare Companies: Conmed (CNMD), Alto Neuroscience, Inc. (ANRO) and Pfizer (PFE) - The Globe and Mail
Alto Neuroscience Inc expected to post a loss of 52 cents a shareEarnings Preview - TradingView
Alto Neuroscience (NYSE:ANRO) Stock Price Expected to Rise, Robert W. Baird Analyst Says - MarketBeat
H.C. Wainwright reiterates Alto Neuroscience stock rating at buy By Investing.com - Investing.com Canada
Stifel reiterates Buy on Alto Neuroscience stock, $33 target By Investing.com - Investing.com Australia
Stifel reiterates Buy on Alto Neuroscience stock, $33 target - Investing.com
Analysts Are Bullish on Top Healthcare Stocks: Alto Neuroscience, Inc. (ANRO), Monte Rosa Therapeutics (GLUE) - The Globe and Mail
Alto Neuroscience: Advancing Precision-Psychiatry Pipeline and De-Risked Trials Support Buy Rating - TipRanks
Alto Neuroscience (NYSE:ANRO) Stock Price Down 3.6%Time to Sell? - MarketBeat
ANRO: ALTO-207 advances in TRD with rapid titration, strong efficacy, and key pipeline catalysts ahead - TradingView
Chardan Capital Reiterates "Buy" Rating for Alto Neuroscience (NYSE:ANRO) - MarketBeat
Alto Neuroscience (NYSE:ANRO) Price Target Raised to $22.00 - MarketBeat
$120M financing supports Alto’s precision neuroscience approach to TRD - The Pharmaletter
Alto raises $120m for resistant depression programme - pharmaphorum
Alto Neuroscience raises $120M to fund depression drug trial By Investing.com - Investing.com South Africa
Alto Neuroscience Reports Strong 2025 Financials, Advances Precision Psychiatry Pipeline with ALTO-207 Acquisition and Key Clinical Milestones - Minichart
Alto Neuroscience Secures $120 Million Private Placement to Fund Phase 3 Study of ALTO-207 for Treatment Resistant Depression - Minichart
Targeting depression, Alto Neuroscience raises $120 million - The Business Journals
Watkins Advises on Alto Neuroscience’s US$120 Million Private Placement Financing - Latham & Watkins LLP
Alto Neuroscience (ANRO) Reports FY25 Loss of $2.19/Share - AlphaStreet
Alto Neuroscience 2025 Annual Report: Precision Psychiatry Platform, Clinical Pipeline, and Intellectual Property Overview - Minichart
Alto Neuroscience, Inc. announced that it expects to receive $119.99969 million in funding from a group of investors - marketscreener.com
Jefferies raises Alto Neuroscience stock price target on pipeline By Investing.com - Investing.com Canada
Alto Neuroscience (NYSE:ANRO) Sets New 1-Year HighHere's Why - MarketBeat
Alto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum - marketscreener.com
Alto Neuroscience Announces $120 Million Private Placement Financing - TradingView
Alto Neuroscience raises $120M to fund depression drug trial - Investing.com
Alto Neuroscience Secures $120 Million Private Placement Financing - TipRanks
Alto Neuroscience (NYSE:ANRO) Posts Earnings Results, Beats Estimates By $0.11 EPS - MarketBeat
Alto Neuroscience (NYSE: ANRO) secures $120M PIPE to fund ALTO-207 - Stock Titan
ANRO: ALTO-207 acquisition and robust cash support multiple pivotal trials through 2028 - TradingView
Alto Neuroscience (NYSE: ANRO) outlines broad precision psychiatry pipeline and IP - Stock Titan
Alto Neuroscience 10-K: Net loss $63.24M, EPS $(2.19) - TradingView
Alto Neuroscience (NYSE: ANRO) posts 2025 loss but extends cash runway to 2028 - Stock Titan
Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights - Business Wire
Wedbush Raises Alto Neuroscience Price Target to $22 From $13, Maintains Neutral Rating - marketscreener.com
Alto Neuroscience (ANRO) to Release Quarterly Earnings on Thursday - MarketBeat
Alto Neuroscience (NYSE:ANRO) Trading 7.3% HigherWhat's Next? - MarketBeat
Alto Neuroscience Stock Pre-Market (-7.0%): Geopolitical Tensions Spark Risk-Off Move - Trefis
12 Health Care Stocks Moving In Monday's After-Market Session - Sahm
VSE Analyst Starts Coverage Optimistically; Check Out the Top 5 Initiations for Monday - Intellectia AI
Alto Neuroscience (NYSE:ANRO) Reaches New 52-Week HighWhat's Next? - MarketBeat
Market Review: What are Alto Neuroscience Incs earnings expectationsPortfolio Profit Report & Low Drawdown Momentum Ideas - baoquankhu1.vn
1.82%
자본화:
|
볼륨(24시간):